Published in Hepatology on May 27, 2014
Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology (2015) 1.08
Use of nontraditional anticoagulants in portal vein thrombosis: a note of caution. Hepatology (2015) 1.06
Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol (2015) 0.94
Portal vein thrombosis. J Clin Exp Hepatol (2015) 0.92
Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci (2016) 0.89
Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis (2016) 0.81
Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban. Clin Mol Hepatol (2016) 0.80
Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology (2014) 0.78
Changing common sense: Anti-platelet/coagulation therapy against cirrhosis. World J Hepatol (2015) 0.75
Reply: To PMID 24395623. Hepatology (2015) 0.75
Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. BMJ Case Rep (2014) 0.75
Thrombotic Venous Diseases of the Liver. J Clin Transl Hepatol (2015) 0.75
Reply: To PMID 24395623. Hepatology (2015) 0.75
Efficacy and Safety of Direct-Acting Oral Anticoagulants Use in Acute Portal Vein Thrombosis Unrelated to Cirrhosis. Gastroenterology Res (2017) 0.75
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med (2009) 0.98
Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study. J Clin Endocrinol Metab (2006) 0.93
Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol (2010) 0.93
De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci (2012) 0.88
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med (2012) 0.87
Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol (2006) 0.85
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol (2010) 0.85
Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int (2014) 0.82
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol (2012) 0.82
Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. J Clin Gastroenterol (2011) 0.81
Drug-Induced Liver Injury. Arch Pathol Lab Med (2015) 0.80
Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med (2012) 0.80
Reply to Martinez-Gonzalez et al. Dig Dis Sci (2015) 0.75
Reply: To PMID 24395623. Hepatology (2015) 0.75
Therapeutic doses of acetaminophen frequently cause elevated aminotransferases in healthy volunteers: is it significant? Gastroenterology (2007) 0.75
Multicenter timolol study: the value of timolol and hemodynamic monitoring in the management of portal hypertensive cirrhotics with no esophageal varices. Gastroenterology (2006) 0.75
Erratum to: Severe Drug-Induced Skin and Liver Injury from Rivaroxaban. Dig Dis Sci (2015) 0.75
Celecoxib-induced Liver Injury: Analysis of Published Case Reports and Cases Reported to the Food and Drug Administration. J Clin Gastroenterol (2017) 0.75
Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci (2015) 0.75
Interrelationship between thyroid nodularity and TSH level. Mt Sinai J Med (2005) 0.75
Serum concentration-dependent hepatotoxicity in individuals receiving oral salsalate. Dig Dis Sci (2008) 0.75